

REMARKS

The Applicants hereby elect to prosecute the claims of Group I, claims 1-17. The Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.

The Examiner has required a species election of an anti-inflammatory agent, as set forth in Claims 6-8; and a pathological condition resulting in loss of neurogenesis as set forth in Claims 9, 10, 12, 13, 16 and 17.

Applicants elect non-steroidal anti-inflammatory agent. Claim 6 reads on the elected species, Claims 1-5 and 9-17 are generic with respect to the elected species.


Applicants elect attenuation by inflammation of neurogenesis in response to surgical interventions, injury or disease. Claim 13 reads on the elected species; Claims 1-8, 14-15 and 17 are generic.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number STAN-303.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: June 15, 2007

By: 
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231